KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Other Non Operating Income (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Other Non Operating Income for 16 consecutive years, with $14.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Non Operating Income rose 142.42% year-over-year to $14.0 million, compared with a TTM value of $13.0 million through Dec 2024, up 120.0%, and an annual FY2025 reading of -$12.0 million, down 200.0% over the prior year.
  • Other Non Operating Income was $14.0 million for Q4 2024 at Thermo Fisher Scientific, up from -$16.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $35.0 million in Q4 2022 and bottomed at -$520.0 million in Q4 2021.
  • Average Other Non Operating Income over 5 years is -$48.4 million, with a median of -$4.0 million recorded in 2022.
  • The sharpest move saw Other Non Operating Income crashed 1625.0% in 2021, then soared 1033.33% in 2022.
  • Year by year, Other Non Operating Income stood at -$40.0 million in 2020, then crashed by 1200.0% to -$520.0 million in 2021, then soared by 106.73% to $35.0 million in 2022, then tumbled by 194.29% to -$33.0 million in 2023, then soared by 142.42% to $14.0 million in 2024.
  • Business Quant data shows Other Non Operating Income for TMO at $14.0 million in Q4 2024, -$16.0 million in Q3 2024, and $5.0 million in Q2 2024.